Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience -- Ignore unavailable to you. Want to Upgrade?

To: Gary D Zehr who wrote (526)	1/25/2000 12:53:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 675

My guess is that folks are finally discovering what a bargain it is--and they've put some of their biotech gains here. I left a message with the company this morning--they're probably getting a busy signal if they're trying to return my call, whoops. The gist of the message was that I'd like to see them get this of the OTC.bb, at times the MM's do not fill orders at all well, I've had trouble with orders sitting all day long, with only the first 500 shares filled--and yet tens of thousands of shares fly across the level II machine. I regard CNSI as a terrific long term invesment, as speculative as any biotech--but it rounds out my portfolio nicely, I've got the gene therapy in there, the genomics and pharmacogenomics, a few cancer angles, the anti-angiogenesis for instance, and I have this little fella--with their GGF2. Imagine owning a biotech for a novel protein! Doesn't sound as sexy as the genome stocks, but I think this is one to hold for quite a few years--I've only had it a year or two, and I add to my position when I have free cash, or when the crummy MM's fill my orders. Expect volatility however, that is just part of the game with these stocks below $5, don't let it shake you up, that is always the trick isn't it--happy to say I snagged quite a few shares when this was below a buck. Actually, if anybody from CNSI reads this thread, you can answer my questions by responding to Mike.McFarland@worldnet.att.net I was also concerned that the recap database may be loaded with a few too many applications for this GGF. It wouldn't be fair if newbies stumbled onto this and thought GGF2 was the cure to everything, I'm as thrilled as anybody when a stock gets pumped up out of the blue, but I'd rather be honest than rich. We are sure to see this get into early clinic trials for a few things, but I think somebody overshot at recap. Any biologists lurking who want to sort out what looks reasonable and what looks like extra stuff from the query? recap.com